T. Rowe Price Investment Management
CGON icon

T. Rowe Price Investment Management’s CG Oncology CGON Stock Holding History

T. Rowe Price Investment Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$455M Buy
6,720,389
+6,297,797
+1,490% +$357M 0.31% 86
2025
Q4 		$17.5M Buy
+422,592
New +$17.5M 0.01% 513
2024
Q3 		– Sell
-66,596
Closed -$2.1M – 629
2024
Q2 		$2.1M Sell
66,596
-642,115
-91% -$22.3M ﹤0.01% 587
2024
Q1 		$31.1M Buy
+708,711
New +$28.9M 0.02% 459

Other funds holding CGON

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management's CGON Position: Q1 2026 in Review

T. Rowe Price Investment Management increased its CG Oncology (CGON) stake by 1,490% in Q1 2026, buying an estimated $357M and bringing the position to 6,720,389 shares worth $455M. The position accounts for 0.31% of the portfolio, ranked #86.

T. Rowe Price Investment Management first reported a position in CGON in Q1 2024 and has held it in 4 quarters since. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • T. Rowe Price Investment Management held 6,720,389 shares of CG Oncology worth $455M as of Q1 2026.
  • T. Rowe Price Investment Management bought 6,297,797 CG Oncology shares in Q1 2026, an estimated $357M.
  • CG Oncology made up 0.31% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #86 holding.
  • T. Rowe Price Investment Management first reported a position in CG Oncology in Q1 2024 and has held it in 4 quarters since.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.